What You Need to Know About Johnson & Johnson's 2020 Third-Quarter Earnings
The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial WorksDid you like reading this story? Click the heart to show your love.
Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 VaccineClick the heart to show your support of this pledge.
The Impact of COVID-19 on a Company: 6 Questions for the Chief Financial Officer of Johnson & JohnsonDid you like reading this story? Click the heart to show your love.
This morning, Johnson & Johnson shared its third-quarter performance.
Since its founding in 1886, the company has grown to become one of the world's largest and most broadly based healthcare companies, with approximately 132,000 employees across the globe working every day to help change the trajectory of health for humanity.
“Johnson & Johnson’s solid third-quarter performance reflects the strength of our business model, the quality and breadth of our portfolio and our relentless drive toward innovation," says COVID-19 vaccine candidate on a not-for-profit basis for pandemic use. The results in these extraordinary times were made possible by our colleagues around the world and their unwavering resilience and focus to deliver value to all of our stakeholders by providing healthcare solutions that benefit people in need globally.”, Executive Vice President, Chief Financial Officer, Johnson & Johnson. "We continue to be driven by our purpose to advance health for humanity as we work to accelerate the development of a safe, effective and affordable investigational
For more details about the company's 2020 third-quarter results, and to read a message from Chairman and Chief Executive Officer, here's an infographic that highlights key stats.
Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.